Semin Liver Dis 2019; 39(04): 452-462
DOI: 10.1055/s-0039-1688503
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Circulating Tumor DNA and Hepatocellular Carcinoma

Ju Dong Yang
1   Division of Digestive and Liver Diseases, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California
2   Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, California
3   Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, California
4   Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
,
Minetta C. Liu
5   Department of Oncology, Mayo Clinic, Rochester, Minnesota
6   Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
,
John B. Kisiel
4   Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
› Author Affiliations
Funding This publication was supported in part by a gift from Mr. and Mrs. David B. Kirshenbaum (JBK).
Further Information

Publication History

Publication Date:
21 June 2019 (online)

Abstract

There is a clear and unmet need for biomarkers in hepatocellular carcinoma (HCC). Circulating cell free deoxyribonucleic acid (cfDNA) is a fragmented DNA subtype, found in the blood circulation. Circulating tumor DNA (ctDNA) is the fraction of total cfDNA, which originates from the primary tumor or metastases in patients with cancer. Earlier studies reported that quantitative measurement cfDNA has diagnostic and prognostic role for HCC. More recently, improvement in next-generation sequencing technology and better understanding of genetic or epigenetic alteration of HCC have allowed comprehensive analysis of mutational and methylation landscape of ctDNA. Hotspot mutation panels and methylation panels have both shown promising performance. None of these tests have yet been validated in longitudinal cohorts for preclinical detection of HCC. In this article, the authors discuss the currently available ctDNA detection technologies, their diagnostic and prognostic performance in HCC, and future research directions.

 
  • References

  • 1 Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ 2018; 362: k2817
  • 2 Yang JD, Mannalithara A, Piscitello AJ. , et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology 2018; 68 (01) 78-88
  • 3 Tzartzeva K, Obi J, Rich NE. , et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018; 154 (06) 1706-1718.e1
  • 4 Yang JD, Addissie BD, Mara KC. , et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev 2018
  • 5 Bettegowda C, Sausen M, Leary RJ. , et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6 (224) 224ra24
  • 6 Fu B, Yan P, Zhang S. , et al. Cell-free circulating methylated Sept9 for noninvasive diagnosis and monitoring of colorectal cancer. Dis Markers 2018; 2018: 6437104
  • 7 Soliman SE, Alhanafy AM, Habib MSE, Hagag M, Ibrahem RAL. Serum circulating cell free DNA as potential diagnostic and prognostic biomarker in non small cell lung cancer. Biochem Biophys Rep 2018; 15: 45-51
  • 8 Lin Z, Neiswender J, Fang B, Ma X, Zhang J, Hu X. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis. Oncotarget 2017; 8 (16) 26625-26636
  • 9 Lautt WW, Greenway CV. Conceptual review of the hepatic vascular bed. Hepatology 1987; 7 (05) 952-963
  • 10 Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. J Hepatol 2016; 65 (05) 1031-1042
  • 11 Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010; 7 (08) 448-458
  • 12 Mandel P, Metais P. [Not Available]. C R Seances Soc Biol Fil 1948; 142 (3-4): 241-243
  • 13 Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 2016; 164 (1-2): 57-68
  • 14 Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012; 63: 199-215
  • 15 Misale S, Yaeger R, Hobor S. , et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486 (7404): 532-536
  • 16 Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 2014; 4 (11) 1269-1280
  • 17 Siravegna G, Mussolin B, Buscarino M. , et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21 (07) 795-801
  • 18 Azad AA, Volik SV, Wyatt AW. , et al. Androgen Receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 2015; 21 (10) 2315-2324
  • 19 Joseph JD, Lu N, Qian J. , et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013; 3 (09) 1020-1029
  • 20 Mohan S, Heitzer E, Ulz P. , et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet 2014; 10 (03) e1004271
  • 21 Diaz Jr LA, Williams RT, Wu J. , et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486 (7404): 537-540
  • 22 Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 2016; 6 (05) 479-491
  • 23 Reinert T, Schøler LV, Thomsen R. , et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 2016; 65 (04) 625-634
  • 24 Douillard JY, Ostoros G, Cobo M. , et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014; 110 (01) 55-62
  • 25 Douillard JY, Ostoros G, Cobo M. , et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014; 9 (09) 1345-1353
  • 26 Newman AM, Bratman SV, To J. , et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014; 20 (05) 548-554
  • 27 Pottekat A, Allawi HT, Boragine GT. , et al. Abstract 4598: a comprehensive assessment of the impact of preanalytical variables on cell free DNA and circulating tumor cells in blood. Cancer Res 2018 ; 78(13, Supplement):Abstract nr 4598
  • 28 Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987; 23 (06) 707-712
  • 29 Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods 2006; 3 (07) 551-559
  • 30 Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW. BEAMing up for detection and quantification of rare sequence variants. Nat Methods 2006; 3 (02) 95-97
  • 31 Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J 2016; 14: 211-222
  • 32 Taly V, Pekin D, Benhaim L. , et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013; 59 (12) 1722-1731
  • 33 Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A 1999; 96 (16) 9236-9241
  • 34 Imperiale TF, Ransohoff DF, Itzkowitz SH. , et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014; 370 (14) 1287-1297
  • 35 Kisiel JB, Dukek BA, Kanipakam R. , et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I Pilot, and phase II clinical validation. Hepatology 2019; 69 (03) 1180-1192
  • 36 Nishimoto S, Fukuda D, Higashikuni Y. , et al. Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance. Sci Adv 2016; 2 (03) e1501332
  • 37 van Boeckel SR, Davidson DJ, Norman JE, Stock SJ. Cell-free fetal DNA and spontaneous preterm birth. Reproduction 2018; 155 (03) R137-R145
  • 38 Jiang P, Chan CW, Chan KC. , et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A 2015; 112 (11) E1317-E1325
  • 39 COSMIC v87, released 13-NOV-18. cancer.sanger.ac.uk/cosmic/ . Accessed 12/11/2018
  • 40 Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 2017; 169 (07) 1327-1341.e1323
  • 41 Huang Z, Hua D, Hu Y. , et al. Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma. Pathol Oncol Res 2012; 18 (02) 271-276
  • 42 Iizuka N, Sakaida I, Moribe T. , et al. Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res 2006; 26 (6C, 6c): 4713-4719
  • 43 Tokuhisa Y, Iizuka N, Sakaida I. , et al. Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 2007; 97 (10) 1399-1403
  • 44 Yan L, Chen Y, Zhou J, Zhao H, Zhang H, Wang G. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma. Int J Infect Dis 2018; 67: 92-97
  • 45 Yang YJ, Chen H, Huang P, Li CH, Dong ZH, Hou YL. Quantification of plasma hTERT DNA in hepatocellular carcinoma patients by quantitative fluorescent polymerase chain reaction. Clin Invest Med 2011; 34 (04) E238
  • 46 Liao W, Mao Y, Ge P. , et al. Value of quantitative and qualitative analyses of circulating cell-free DNA as diagnostic tools for hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) 2015; 94 (14) e722
  • 47 Piciocchi M, Cardin R, Vitale A. , et al. Circulating free DNA in the progression of liver damage to hepatocellular carcinoma. Hepatol Int 2013; 7 (04) 1050-1057
  • 48 Ren N, Qin LX, Tu H, Liu YK, Zhang BH, Tang ZY. The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132 (06) 399-407
  • 49 Chen H, Sun LY, Zheng HQ, Zhang QF, Jin XM. Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. Pathology 2012; 44 (04) 318-324
  • 50 Zhai W, Lim TK, Zhang T. , et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat Commun 2017; 8: 4565
  • 51 Liao W, Yang H, Xu H. , et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget 2016; 7 (26) 40481-40490
  • 52 Huang A, Zhang X, Zhou SL. , et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer 2016; 7 (13) 1907-1914
  • 53 Jiao J, Watt GP, Stevenson HL. , et al. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: prevalence and risk factors. Hepatol Commun 2018; 2 (06) 718-731
  • 54 Marchio A, Amougou Atsama M, Béré A. , et al. Droplet digital PCR detects high rate of TP53 R249S mutants in cell-free DNA of middle African patients with hepatocellular carcinoma. Clin Exp Med 2018; 18 (03) 421-431
  • 55 Jiao J, Niu W, Wang Y. , et al. Prevalence of aflatoxin-associated TP53R249S mutation in hepatocellular carcinoma in Hispanics in South Texas. Cancer Prev Res (Phila) 2018; 11 (02) 103-112
  • 56 Yang JD, Mohamed EA, Aziz AO. , et al; Africa Network for Gastrointestinal and Liver Diseases. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol 2017; 2 (02) 103-111
  • 57 Ng CKY, Di Costanzo GG, Tosti N. , et al. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study. Ann Oncol 2018; 29 (05) 1286-1291
  • 58 Ikeda S, Tsigelny IF, Skjevik AA. , et al. Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma. Oncologist 2018; 23 (05) 586-593
  • 59 Riviere P, Fanta PT, Ikeda S, Baumgartner J, Heestand GM, Kurzrock R. The mutational landscape of gastrointestinal malignancies as reflected by circulating tumor DNA. Mol Cancer Ther 2018; 17 (01) 297-305
  • 60 Labgaa I, Villacorta-Martin C, D'Avola D. , et al. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene 2018; 37 (27) 3740-3752
  • 61 Huang A, Zhao X, Yang XR. , et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. J Hepatol 2017; 67 (02) 293-301
  • 62 Cohen JD, Li L, Wang Y. , et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018; 359 (6378): 926-930
  • 63 Villanueva A, Portela A, Sayols S. , et al; HEPTROMIC Consortium. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology 2015; 61 (06) 1945-1956
  • 64 Hlady RA, Robertson KD. Genetic and epigenetic heterogeneity in normal liver homeostasis and its implications for liver disease and hepatocellular cancer. Semin Liver Dis 2018; 38 (01) 41-50
  • 65 Lehmann-Werman R, Neiman D, Zemmour H. , et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci U S A 2016; 113 (13) E1826-E1834
  • 66 Sun K, Jiang P, Chan KC. , et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A 2015; 112 (40) E5503-E5512
  • 67 Wong IH, Lo YM, Zhang J. , et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999; 59 (01) 71-73
  • 68 Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 2000; 6 (09) 3516-3521
  • 69 Wang J, Qin Y, Li B, Sun Z, Yang B. Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem 2006; 39 (04) 344-348
  • 70 Iyer P, Zekri AR, Hung CW. , et al. Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Exp Mol Pathol 2010; 88 (01) 107-111
  • 71 Huang G, Krocker JD, Kirk JL. , et al. Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma. Clin Chem Lab Med 2014; 52 (06) 899-909
  • 72 Chu HJ, Heo J, Seo SB. , et al. Detection of aberrant p16INK4A methylation in sera of patients with liver cirrhosis and hepatocellular carcinoma. J Korean Med Sci 2004; 19 (01) 83-86
  • 73 Zhong S, Yeo W, Tang MW, Wong N, Lai PB, Johnson PJ. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin Cancer Res 2003; 9 (09) 3376-3382
  • 74 Zhang YJ, Wu HC, Shen J. , et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res 2007; 13 (08) 2378-2384
  • 75 Chan KC, Lai PB, Mok TS. , et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 2008; 54 (09) 1528-1536
  • 76 Yeo W, Wong N, Wong WL, Lai PB, Zhong S, Johnson PJ. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int 2005; 25 (02) 266-272
  • 77 Mohamed NA, Swify EM, Amin NF, Soliman MM, Tag-Eldin LM, Elsherbiny NM. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?. Arab J Gastroenterol 2012; 13 (03) 111-115
  • 78 Oussalah A, Rischer S, Bensenane M. , et al. Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. EBioMedicine 2018; 30: 138-147
  • 79 Holmila R, Sklias A, Muller DC. , et al. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma. PLoS One 2017; 12 (03) e0174265
  • 80 Sun FK, Fan YC, Zhao J. , et al. Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients. Dig Dis Sci 2013; 58 (04) 1010-1015
  • 81 Han LY, Fan YC, Mu NN. , et al. Aberrant DNA methylation of G-protein-coupled bile acid receptor Gpbar1 (TGR5) is a potential biomarker for hepatitis B Virus associated hepatocellular carcinoma. Int J Med Sci 2014; 11 (02) 164-171
  • 82 Ji XF, Fan YC, Gao S, Yang Y, Zhang JJ, Wang K. MT1M and MT1G promoter methylation as biomarkers for hepatocellular carcinoma. World J Gastroenterol 2014; 20 (16) 4723-4729
  • 83 Tangkijvanich P, Hourpai N, Rattanatanyong P, Wisedopas N, Mahachai V, Mutirangura A. Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma. Clin Chim Acta 2007; 379 (1-2): 127-133
  • 84 Wen L, Li J, Guo H. , et al. Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients. Cell Res 2015; 25 (11) 1250-1264
  • 85 Xu RH, Wei W, Krawczyk M. , et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16 (11) 1155-1161
  • 86 Ono A, Fujimoto A, Yamamoto Y. , et al. Circulating tumor DNA analysis for liver cancers and its usefulness as a liquid biopsy. Cell Mol Gastroenterol Hepatol 2015; 1 (05) 516-534
  • 87 Li F, Qiao CY, Gao S, Fan YC, Chen LY, Wang K. Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy. Free Radic Res 2018; 52 (04) 455-464
  • 88 Pepe MS, Etzioni R, Feng Z. , et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001; 93 (14) 1054-1061
  • 89 Okajima W, Komatsu S, Ichikawa D. , et al. Liquid biopsy in patients with hepatocellular carcinoma: circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2017; 23 (31) 5650-5668
  • 90 Grimm SA, Shimbo T, Takaku M. , et al; NISC Comparative Sequencing Program. DNA methylation in mice is influenced by genetics as well as sex and life experience. Nat Commun 2019; 10 (01) 305
  • 91 Kader F, Ghai M. DNA methylation-based variation between human populations. Mol Genet Genomics 2017; 292 (01) 5-35